Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 8, 2024

Short-term Group Venetoclax Combined with Azacitidine for Treating Newly Diagnosed Elderly Acute Myeloid Leukemia: A Retrospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ZYZhuruohan YuSLShuangyue LiRPRenzhi Pei

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yu et al. (2024) studied this question.

synapsesocial.com/papers/68e61090b6db6435875a3ca8https://doi.org/10.21203/rs.3.rs-4569429/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with azacitidine in elderly acute myeloid leukemia: A retrospective comparison of 14-day vs 28-day dosing regimens2025 · 2 citations
  2. 2Dose-adjusted treatment with venetoclax for 7 days and 5-azacitidine or decitabine in patients with Acute Myeloid Leukemia or higher risk myelodysplastic neoplasms2025
  3. 3Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial2025 · 1 citations
  4. 4Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China2026
  5. 5Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center study2025 · 2 citations